Abstract
The versatile synthon E-methyl 2-(2-(1,3-dioxo-1-arylpropan-2-ylidene) hydrazinyl) benzoate has a potent cytotoxic activity, which was screened in vitro for anticancer activity against human hepatocellular carcinoma cell (HCC) line. The results show a higher anticancer efficacy and higher selectivity index (SI) on HCC versus doxorubicin that warrants further studies in both animals and humans; this work has been patented.